WallStSmart

Alumis Inc (ALMS)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Alumis Inc generates 897% more annual revenue ($7.40M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. ALMS earns a higher WallStSmart Score of 25/100 (F).

ALMS

Avoid

25

out of 100

Grade: F

Growth: 3.7Profit: 2.5Value: 5.0Quality: 7.0
Piotroski: 4/9Altman Z: -2.68

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ALMS2 strengths · Avg: 9.0/10
Debt/EquityHealth
0.0810/10

Conservative balance sheet, low leverage

Price/BookValuation
2.6x8/10

Reasonable price relative to book value

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.259/10

Conservative balance sheet, low leverage

Areas to Watch

ALMS4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.28B3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-41.9%2/10

ROE of -41.9% — below average capital efficiency

RVMD4 concerns · Avg: 3.5/10
Price/BookValuation
16.8x4/10

Trading at 16.8x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : ALMS

The strongest argument for ALMS centers on Debt/Equity, Price/Book.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : ALMS

The primary concerns for ALMS are EPS Growth, Market Cap, Profit Margin.

Bear Case : RVMD

The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.

Key Dynamics to Monitor

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

ALMS is growing revenue faster at -37.7% — sustainability is the question.

ALMS generates stronger free cash flow (-82M), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ALMS scores higher overall (25/100 vs 24/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Alumis Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Alumis Inc. (ALMS) is a prominent player in the aluminum sector, specializing in the development and commercialization of high-performance aluminum solutions for automotive, aerospace, and construction industries. By harnessing proprietary technologies and a commitment to sustainability, Alumis not only drives innovation in materials science but also prioritizes environmental responsibility. The company's strong focus on research and development enables it to adapt to emerging market trends, resulting in a diverse product portfolio designed to meet the dynamic needs of its clients. With a commitment to operational excellence, Alumis is well-positioned to achieve sustained growth and deliver long-term value for investors.

Visit Website →

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?